Introducing affinity and selectivity into galectin-targeting nanoparticles with fluorinated glycan ligands by Richards, Sarah-Jane et al.
This is a repository copy of Introducing affinity and selectivity into galectin-targeting 
nanoparticles with fluorinated glycan ligands.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/168045/
Version: Accepted Version
Article:
Richards, Sarah-Jane, Keenan, Tessa, Vendeville, Jean-Baptiste et al. (12 more authors) 
(2020) Introducing affinity and selectivity into galectin-targeting nanoparticles with 
fluorinated glycan ligands. Chemical Science. ISSN 2041-6539 
https://doi.org/10.1039/D0SC05360K
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
! !
!
ARTICLE 
  
Please do not adjust margins 
Please do not adjust margins 
 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
!
Introducing affinity and selectivity into galectin-targeting 
nanoparticles with fluorinated glycan ligands.   
Sarah-Jane Richards,a! Tessa Keenan,d! Jean-Baptiste Vendeveille,e David E. Wheatley,e Harriet 
Chidwick,d Darshita Budhadev,d Claire E. Council,e Claire S. Webster,f Helene Ledru,f Alexander N. 
Baker,a Marc Walker,c M. Carmen Galan,f Bruno Linclau,* Martin A. Fascione,d * Matthew I. 
Gibson,a,b *  
Galectins are potential biomarkers and therapeutic targets. However, galectins display broad affinity towards β-galactosides 
meaning glycan-based (nano)biosensors lack the required selectivity and affinity. Using a polymer-stabilized nanoparticle 
biosensing platform, we herein demonstrate that the specificity of immobilised lacto-N-biose towards galectins can be 
‘turned on/off’ by using site-specific glycan fluorination and in some cases reversal of specificity can be achieved. The panel 
of fluoro-glycans were obtained by a chemoenzymatic approach, exploiting BiGalK and BiGalHexNAcP enzymes from 
Bifidobacterium infantis which are shown to tolerate fluorinated glycans, introducing structural diversity which would be 
very laborious by chemical methods alone. These results demonstrate that integrating non-natural, fluorinated glycans into 
nanomaterials can encode unprecedented selectivity with potential applications in biosensing.
Introduction 
Galectins are a large group of soluble β-galactoside binding 
proteins which are targets for therapy and diagnostics, 
compared to other human lectin families which are typically 
membrane-bound.1–3 Galectin-3 for example is overexpressed 
in prostate cancers4 leading to endothelial cell adhesion,5 
nanomolar glycopeptide inhibitors of Galectin-3 have been 
shown to suppress metastasis6 and several galectin-binders 
have advanced to clinical trials. 7 However, as all galectins bind 
terminal β-galactosides to some extent, it is a significant 
challenge to selectively target individual galectins.2 Percec and 
co-workers have employed dendrimeric scaffolds to probe how 
multivalent presentation of glycans affects galectin binding 
showing how topology and ligand density can be used to tune 
affinity.8,9 Despite the promise of using glycans to detect 
analytes, antibody reagents remain the main clinical tools used 
in ELISA,10 lateral flow11 or flow cytometry assays.  
The installation of glycans onto polymer-coated gold 
nanoparticles is a powerful technology to probe lectin binding. 
12,13 The polymer coating provides steric stabilization to prevent 
aggregation in complex media, and the incorporation of 
multiple copies of a glycan at the polymer chain ends, increasing 
affinity due to the cluster glycoside effect.14 Gold nanoparticles 
have unique optical properties,15,16 which enables signal 
generation through aggregation13,17–19 in lateral flow 
devices,20,21 and also in surface enhanced Raman 
spectroscopy.22 However, most studies with multivalent glycans 
involve mono/di-saccharides which have shown limited 
selectivity so far.23 There is therefore a knowledge and 
technological gap, to develop synthetically-accessible 
multivalent probes, which are also endowed with selectivity.24  
Fluorination of glycans influences their physicochemical 
properties and hence modulates their biological function.25–28 
While fluorine substitution has little effect on glycan 
conformation,29,30 it can influence hydrogen bonding properties 
of adjacent hydroxyl groups,31,32 and fluorine itself is a weak 
hydrogen bond acceptor but not a hydrogen bond donor.33,34 
Furthermore, fluorine atoms can form attractive multipolar 
interactions with proteins,35,36 and these have been observed 
with fluorinated carbohydrate derivatives,37 including galectin 
binders.38 Fluorinated sialyl oligosaccharides displayed 
significantly higher binding affinities for the Toxoplasma gondii 
lectin, TgMIC1 in comparison to their non-fluorinated 
counterparts.39 Similarly, fluorinated MUC-1 antigens displayed 
enhanced immunogenicity and differential binding affinity to 
mouse antisera, making them useful tools for probing humoral 
immune responses.40 Fluorinated glycans have also proven 
effective for probing carbohydrate-lectin structure-activity 
relationships. For example, Glcα1-3ManαMe analogues 
fluorinated around the Glc moiety revealed that the 2- and 3-
OH group of Glc were important for calreticulin binding, but not 
the 6-OH.41 Similarly, the 6-OH group of the α-1,6-branched 
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mannose in the Man3GlcNAc2 glycan, was shown to be 
important for Concanavalin A binding.42  
A powerful route to diversify un-natural glycans is to 
incorporate an enzymatic step. By using promiscuous enzymes 
for glycosidic bond formation,27 which are capable of accepting 
chemically accessible fluorinated glycans, building blocks can be 
combined, producing anomerically pure compounds, facilitating 
purification. 
Herein we report a chemoenzymatic route to selectively 
fluorinated lacto-N-biose (Gal-β1-3)-GlcNAc) glycans, including 
fluorination at both sugar residues, and their integration into a 
multivalent glyconanoparticle platform. We demonstrate that 
site-selective fluorination enables modulation of the affinity 
and introduces high selectivity towards galectins 3 and 7 which 
is not possible using native glycans. This approach 
demonstrates the potential for the translation of 
glyconanomaterials to applications in therapy and biosensing. 
Results and Discussion 
Lacto-N-biose has confirmed affinity towards Galectin-3,43 so a 
library of nine fluorinated lacto-N-biose derivatives was 
synthesised, using a modular chemoenzymatic approach (Figure 
1 and ESI). Glycans were designed with an azido-propyl tether 
for subsequent nanoparticle immobilization.17,44 This strategy 
introduces diversity through the chemical fluorination of the 
individual monosaccharide building blocks, galactose (Gal) and 
N-acetylglucosamine (GlcNAc), prior to enzymatic glycosylation 
using a one-pot, two enzyme strategy. In this system, the kinase 
BiGalK45 catalyses the formation of galactose-1-phosphates 
(Gal-1Ps), before the phosphorylase BiGalHexNAcP46-catalyzed 
transfer of Gal-1Ps to GlcNAc acceptors, by reverse 
phosphorylysis.47 As several fluorinated Gal derivatives are 
commercially available, we focused on chemical diversification 
of the GlcNAc acceptor. BiGalHexNAcP was previously shown to 
be highly tolerant to modifications at the 2- and 6-positions of 
GlcNAc and GalNAc,46 so we focused our efforts on introducing 
fluorine to these positions (Figure 1A). During a preliminary 
screen for BiGalHexNAcP donor specificity, we found Gal (9), 
3FGal (10) and 6FGal (11) to be suitable donors, while little or 
no activity was displayed towards 2FGal (12) and 4FGal (13) in 
the one-pot, two enzyme system, when using GlcNAc-N3 (14) as 
the acceptor (data not shown). Lacto-N-biose and fluorinated 
derivatives were efficiently synthesized on semi-preparative 
scale using donors 9-11 and acceptors 5-8 & 14 (Figure 1B and 
ESI). Excess amounts of donor sugar (2 - 10 equiv.) were used to 
drive the reactions towards disaccharide formation. For the less 
preferred substrates (e.g. 3FGal), extended reaction times (up 
to 144 h) and the sequential addition of enzyme were used to 
achieve maximum conversion. As high purity was required, all 
glycans were subjected to a two-step purification (gel filtration 
and flash or anion-exchange chromatography). In total, eight 
fluorinated disaccharides (16-23) bearing aminopropyl azide 
linkers were prepared, in addition to lacto-N-biose derivative  
(15), in isolated yields ranging from 25 – 76%. 
 
 
Figure 1. A. Chemical syntheses of fluorinated acceptors. B) 
Fluorinated lacto-!-biose analogues prepared using a 
chemoenzymatic strategy with BiGalK and BiGalHexNAcP. 
TFA = trifluoroacetyl. 
 
PHEA(poly(hydroxylethyl acrylamide)) coated gold 
nanoparticles were selected for the screening, as these are an 
established platform for glycan binding analysis.5,39 This tool 
requires small (µg) quantitates of glycans and hence is ideal for 
screening compared to calorimetry or NMR-based approaches 
which need more material, which is not always available. RAFT 
(reversible addition-fragmentation chain transfer) 
polymerization was used to obtain telechelic PHEA ligands 
bearing a pentafluorophenyl (PFP) group at the α-terminus 
(Figure 2A).44,48 The PFP was displaced by dibenzocyclooctyne-
amine, introducing a handle (validated by 19F NMR) to capture 
the glycosyl azide, by strain promoted azide/alkyne click 
(SPAAC). By using RAFT, an ω−terminal thiol was also produced 
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enabling assembly of the glycoligands onto 55 nm gold 
nanoparticles with excess polymer removed by 
centrifugation/resuspension cycles. The nanoparticle size and 
polymer chain length (DP25) used were guided by previous 
work, to give a balance between colloidal stability and 
aggregation responses.39 UV-Visible spectroscopy showed the 
characteristic SPR band (533 nm) and no aggregation (at 700 
nm) after polymer coating (Figure 2B). Dynamic light scattering 
showed a small increase in hydrodynamic diameter consistent 
with polymer coating (Figure 2C). X-ray photoelectron 
spectroscopy (XPS, in ESI) confirmed the presence of the 
polymers and the fluorine from the glycans.  
 
 
Figure 2. Nanoparticle synthesis and characterization. A) 
Synthetic route to conjugate fluoro-glycans onto nanoparticles; 
B) UV-Vis traces of all nanoparticles showing colloidal stability; 
C) Dynamic light scattering (DLS) of all nanoparticles showing 
size increase upon polymer coating. 
 
With this panel of fluoro-glycan nanoparticles (GlycoAuNPs) in 
hand, their lectin binding affinity/selectively trends could be 
evaluated, initially using soybean agglutinin (SBA) which 
preferentially binds β-D-galactosides.13,49 Binding was assessed 
by exploiting the optical properties of the GlycoAuNPs, whereby 
SBA binding leads to aggregation of the nanoparticles (Figure 
3A). This results in a red-blue color shift which can be assessed 
by UV-Visible spectroscopy (Figure 3B).17,18,50 As expected, 
lacto-N-biose (15) showed weak affinity towards SBA 
(KD,apparent >10 μM; KD values for multivalent systems are very 
challenging to determine). Fluorine addition to the GlcNAc unit 
improved the binding >12-fold, where Gal-β(1,3)-6FGlcNTFA 
(20, dark blue line), Gal-β(1,3)-6,6diFGlcNAc (22, pink line) and 
Gal-β(1,3)-6,6diFGlcNTFA (23, green line) all show KD,apparent 
values in the range of 0.84-0.89 μM. Furthermore Gal-β(1,3)-
6FGlcNAc (18, dark purple line) does not have sufficient fluorine 
incorporation to see this increase in binding. Fluorination in any 
position around the galactose ring was not tolerated, resulting 
in decreased binding affinity in the cases of 6FGal-β(1,3)-
6FGlcNTFA (21) compared to Gal-β(1,3)-6FGlcNTFA (20).  
Guided by these experiments with SBA, Galectin-3 binding was 
profiled (Figure 3C). Galectin-3 has only a single binding site, but 
is in equilibrium with a pentameric form, and hence can cross-
link multivalent glycomaterials.51 Lacto-N-biose (15) particles 
bound Galectin-3, agreeing with previous observations from 
Hsieh et al.43 However, a number of fluorinated lacto-N-biose 
derivatives bound with a greater affinity to Galectin-3 than 
native (15), with 3FGal-β(1,3)-GlcNAc (16), Gal-β(1,3)-
6,6diFGlcNTFA (23), Gal-β(1,3)-6FGlcNTFA (20) and Gal-β1(1,3)-
6,6diFGlcNAc (22) all showing enhanced binding. In contrast, 
any glycan with a 6FGal derivative, such as 6FGal-β(1,3)-GlcNAc 
(17), 6FGal-β(1,3)-6FGlcNAc (19) and 6FGal-β(1,3)-6FGlcNTFA 
(21)) completely ‘switched off’ the binding to Galectin-3. Kinetic 
analysis of aggregation agreed with dose-response (Figure 3D) 
data, with 3FGal-β(1,3)-GlcNAc (16) showing the fastest rate. 
This was confirmed by dynamic light scattering (Figure 3E) 
showing that ‘non-binder’ 6FGal-β(1,3)-6FGlcNTFA (21) does 
not lead to aggregation. This provides strong evidence that 
subtle site-specific fluorination is a powerful tool to introduce 
affinity and selectivity into glycans against biomedically relevant 
lectins, when conjugated to nanoparticles.  
 
 
Figure 3. Screening of lectin/F-GlycoNP binding. A) Schematic of 
aggregation assay; B) Dose response to Soy Bean Agglutinin 
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(SBA); C) Dose response to Galectin-3; D) Aggregation kinetics 
with Galectin-3; E) Dynamic light scattering with Galectin-3.  
To further validate the aggregation-based assays, biolayer 
interferometry (BLI) was employed.12 Galectin-3 was 
biotinylated, then immobilized onto streptavidin-functional BLI 
sensors, and the GlycoAuNPs applied (Figure 4). Lacto-N-biose 
(15, Figure 4A) showed little binding due to the concentrations 
used (to enable enhancements to be observed without 
saturation). In agreement with the aggregation-based assays, 
significant binding was observed using 3FGal-β(1,3)-GlcNAc (16, 
Figure 4B), and there was some limited binding observed with 
Gal-β(1,3)-6FGlcNTFA (20, Figure 4C)). Also in line with the 
aggregation data, no binding was seen for 6FGalβ(1,3)-
6FGlcNTFA (21, Figure 4D). Indeed, consideration of the crystal 
structure (PDB entry 4XBN43) of Galectin-3 with lacto-N-biose 
reveals an interaction of the 6-OH of galactose with residues 
Asn174A/Glu184A, supporting our observation that 6-OH 
replacement with fluorine is detrimental for binding. The 3-OH 
group is not involved in H-bonding interactions and hence 
fluorination does not diminish binding, and instead appears to 
increase the overall affinity. Overall, these data conclusively 
show that site-specific fluorination enables precise modulation 
of binding affinity and could be used to generate nanoparticle 
biosensors for rapid detection of this important biomarker. 
 
 
Figure 4. Biolayer interferometry analysis of binding of AuNPs 
to Galectin-3. A) Lacto-N-biose (15); B) 3FGal-β(1,3)-GlcNAc 
(16); C) Gal-β(1,3)-6FGlcNTFA, (20); D) 6FGal-β(1,3)-6FGlcNTFA, 
(21).  
 
Encouraged by the Galectin-3 binding data, the utility of these 
unique fluoro-glycan nanoparticles to discriminate between 
individual galectins was explored, which is often not possible 
with natural glycans nor with monosaccharide-based 
glycomaterials. Galectin-7 was chosen as it has previously been 
reported to have lower affinity towards lacto-N-biose (270 µM) 
than Galectin 3 (93 µM)43 and hence offers a robust challenge 
to explore how fluorination can be used to tune 
specificity/affinity. Binding of Galectin-7 to the library of 
particles by the aggregation assay (as described above) was 
conducted, and Figure 5 shows the relative affinities as 
KD,apparent. Lacto-N-biose particles showed preference for 
Galectin 3 as anticipated, displaying limited binding to Galectin-
7 in the concentration range tested. Introduction of fluorine 
atoms resulted in a variation of the observed Kd’s, but in 
particular 6FGalβ(1,3)-6FGlcNTFA (21) showed switching of 
affinity compared to non-fluorinated ligands: this derivative 
showed no affinity to Galectin-3, but the fluorination results in 
‘switching on’ of affinity towards Galectin-7. The extent of 
aggregation at plateau for 21 was lower than for 15, but clear 
binding was seen. It is important to highlight that these assays 
cannot identify if glycans engage the protein in the same 
manner, or at different (non-canonical) binding sites. This 
affinity switch shows that the site-specific incorporation of 
fluorine atoms can overcome the low selectivity of glycans 
towards their lectin partners and in some cases completely turn 
off interactions. Additional glycan modifications to a core 
lactosyl unit in a glycan array have also been reported to 
modulate galectin binding pattern, which is complementary to 
the approach taken here.52 Such selectivity is essential in the 
development of glyconano tools for therapy and diagnostics. 
Furthermore, this chemoenzymatic synthetic approach to 
glycan libraries may facilitate screening of binding epitopes by 
method such as (STD) NMR53–55 which require more material 
and have lower throughput.  
 
 
Figure 5. Galectin-7 binding to the F-glyconanoparticle library. 
A) Dose-response curve for the AuNP aggregation assay; B) 
Summary of apparent Kd (nM) for selected glycans showing the 
fine-tuning and selectivity inversion. (-) = no binding  
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Full experiment details are in the electronic Supporting 
Information. This includes characterization of all glycans and 
nanomaterials.  
Conclusions 
To conclude, a chemoenzymatic glycosylation strategy was 
employed for the rapid assembly of a diverse library of 
(multi)fluorinated lacto-N-biose derivatives, which were 
integrated into nanobiosensors. The efficient one-pot 
enzymatic glycosylation process confines the protecting group 
requirements to the chemical synthesis of the fluorinated 
acceptors, and reveals a large substrate tolerance of the BiGalK 
and BiGalHexNAcP enzymes. These fluoro-glycans were 
conjugated to polymer-stabilized gold nanoparticles, which 
were used to reveal unique binding patterns and significant 
enhancements in selectivity towards two Galectins. Due to the 
use of nanoparticles, only very low amounts (ug) of glycan per 
assay are required in contrast to other methods. It was 
discovered that a single fluorine at 3-position of the galactose 
residue dramatically enhanced binding towards Galectin-3. 
Fluorine at other locations dramatically reduced binding, with 
6-fluorination abrogating all binding affinity. Galectin-7 was also 
screened which does not normally show any significant binding 
to the native lacto-N-biose. It was shown that selective 
fluorination allowed complete reversal of selectivity such that a 
pentafluorinated derivative only bound Galectin-7 and all 
binding to Galectin-3 was removed, which is an unprecedented 
switch in selectivity. This is notable as glycans normally display 
a range of binding affinities but here fluorination enables the 
introduction of binary on/off responses which may be useful in 
the design of biosensors, and innovative diagnostics. These 
findings show that subtle fluorination strategies can engineer 
marked selectivity into immobilized glycans. This will aid the 
development of new sensing platforms which are not accessible 
using native mono/disaccharides due to their broad binding 
affinities, and the development of glycan-diagnostics as 
alternatives to traditional antibody-based techniques.  
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